Recent progress in understanding the pathogenicity of multiple sclerosis (MS) has enabled us to develop new drug entities available in the clinic. However, we still have not succeeded in preventing conversion from relapsing-remitting MS to secondary progressive MS (SP-MS), and in curing this intractable form of MS. Furthermore, diagnosis is usually retrospective, relying on gradual worsening of neurological signs/symptoms. This is due to the lack of understanding of the pathogenicity driving disease progression in MS and of reliable biomarkers reflecting the disease status. Two relevant components are involved in the brain pathology of SP-MS: neurodegeneration and inflammation. Neurodegeneration can occur spontaneously in a neuron-intrinsic manner under chronic inflammation, such as glutamate excitotoxicity, mitochondrial/oxidative injury with iron deposit in the brain and loss of trophic support. Meanwhile, inflammatory and/or immune cells stimulated after repeated relapses, including T cells, B cells, and myeloid cells of peripheral and central nervous system origin, could mediate the processes of neurodegeneration. Among them, a higher frequency of leptomeningeal follicle-like structures observed in SP-MS patients suggests that immune cells sheltered behind a blood-brain barrier are still active under smoldering central nervous system inflammation. Accordingly, our recent comparative analysis between MS and its animal model, experimental autoimmune encephalomyelitis, raises a new possibility that ectopic expression of eomesodermin in helper T cells constitutes a previously unappreciated subset of helper T cells with cytotoxic potential against neuronal cells. In the present review article, the mechanisms proposed in the pathogenesis of SP-MS are summarized, and a new pathogenic mechanism for neurodegeneration mediated by unique cytotoxic helper T cells is proposed.
Introduction
As a result of the rapid and spectacular technological innovation in genetic analysis, genome-wide association studies have successfully shown the involvement of a significant number of genes associated with the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). [1] [2] [3] [4] Interestingly, most of the susceptibility genes associated with the pathogenesis of MS have been integrated into those involved in the regulation of helper T (Th) cell function and cellular immune responses. 4 These data clearly show the pivotal roles of acquired immunity, especially the regulation and maintenance of differentiation and functions of Th cells, in the development of relapsing-remitting MS (RR-MS). During the disease course of MS, an inflammatory cascade triggered by infiltration of pathogenic T cells that secrete interferon (IFN)-c, interleukin (IL)-17 and other inflammatory cytokines promotes demyelination and axonal degeneration characteristic of MS lesions. [5] [6] [7] Consequently, a better understanding of the pathogenesis of the disease during the past decades has enabled the expansion of disease-modifying therapies. Namely, conventional IFN-b that reduces relapse rates and severity through modulation of general immune responses has long been used for treatment of MS. Meanwhile, anti-a4 integrin antibody (natarizumab) and sphingosine-1-phosphate receptor type 1 agonist (fingolimod) that inhibit the mobilization and accumulation of T cells into the central nervous system (CNS), and glatiramer acetate (copolymer-1) that attenuates excessive T-cell activation through acting as a decoy for myelin antigens have been recently introduced. In contrast, current therapeutic options for progressive forms of MS, including primary progressive MS (PP-MS) and secondary progressive MS (SP-MS), remain poor in comparison with those for RR-MS. Furthermore, diagnosis for SP-MS is based on patients' medical history of neurological deterioration with or without relapses after long-term medical follow up. Although classification criteria for progressive MS have been recently revised, diagnosis of SP-MS remains retrospective in principle. 8 Here, precise diagnosis of progressive MS requires novel biomarkers that faithfully reflect ongoing progression of the symptoms in SP-MS. One apparent reason for this is a lack of a precise understanding of the pathomechanisms driving the progressive form of MS and reliable biomarkers reflecting their disease status, which enable identification of therapeutic target molecule(s) and differential diagnosis. 9 RR-MS and SP-MS are shown to have different pathological features. RR-MS is more associated with massive inflammation, recurrent entry of immune cells into CNS, disturbance of the blood-brain barrier (BBB) and active CNS lesions. Meanwhile, SP-MS is more relevant to smoldering inflammation restricted within CNS, leptomeningeal inflammatory aggregates (follicle-like structures [FLS] ), slow expansion of persistent lesions, subpial cortical demyelination and brain atrophy. There are numerous hypothetical mechanisms that explain leptmeningeal formation of FLS, cortical demyelination and neurodegeneration associated with SP-MS. Neurodegeneration and chronic inflammation are considered to be two components involved in brain damage in SP-MS. However, development of neurodegeneration and chronic inflammation could occur either simultaneously or independently, and mutual association between these two components is not clear so far. In the present review, the possible mechanisms proposed to date on the pathogenesis of SP-MS are summarized. A new pathogenic mechanism for neurodegeneration by unique cytotoxic Th cells based on our recent progress in research for SP-MS pathogenesis is also proposed. 10 Proposed pathogenic mechanism of secondary progressive MS Neuron-intrinsic mechanisms of neurodegeneration and axonal dysfunction Prevention of progression in neurological diseases, such as MS and many other neurodegenerative diseases, remain an obvious challenge in the field of clinical research. Although it is not well elucidated why and how conversion of the disease from RR-MS to SP-MS takes place, inflammation and neurodegeneration, which are not necessarily mutually exclusive, are two key components strongly associated with progressive MS. [11] [12] [13] Currently, CNSautonomous events associated with neurodegeneration, such as microglial activation, mitochondrial injury, glutamate excitotoxicity, loss of trophic support and so on, are believed to be major components associated with progressive MS.
Microglial activation
Microglial activation is one of the most common features of active tissue injury, not only in MS, but also in other neuroinflammatory and neurodegenerative diseases.
14 Interestingly, activation of microglia is not restricted to lesions, but is observed in normalappearing white and grey matter of patients with progressive MS. 15 Therefore, microglial activation is prerequisite for foundation of prolonged inflammatory milieu in the CNS, followed by active lesion formation, and additional components are required to trigger variable tissue damage. Activated microglia are proposed to damage directly both oligodendrocytes and neurons through the secretion of proinflammatory cytokines and reactive oxygen and nitrogen species, respectively.
16,17
Mitochondrial injury Mitochondria are known to be highly susceptible to oxidative injury, and reactive oxygen and nitrogen species impair activity of respiratory chain complexes in mitochondria. Therefore, consequent energy failure caused by mitochondrial dysfunction can lead to axonal degeneration and neuronal cell death. 18 Furthermore, mitochondrial damage can induce the release of oxygen radicals as a byproduct of impaired respiratory chain reaction, forming a vicious cycle of tissue injury. 19 Interestingly, iron released from dying oligodendrocytes accumulates in microglia, astrocyte and neurons at the edges and centers of lesions in MS patients. 20 Glutamate excitotoxicity Glutamate is one of the major excitatory neurotransmitters of the CNS. Functional dysregulation of glutamate transporters leads to an abnormal increase of extracellular glutamate. Excitotoxicity caused by exposure to excess glutamate is directly toxic to neurons. 21 Indeed, sustained activation of glutamate receptors induces an excess of intra-axonal Ca 2+ and concomitant axonal degeneration. However, the cellular source of glutamate involved in the individual process of relapsing-remitting and progressive MS could differ, and it is still controversial whether normalization of excess glutamate release is feasible. In any case, glutamate-scavenging therapy using glutamate oxaloacetate transaminase might be beneficial for the treatment of MS. 22 Dysregulated distribution of the ion channel Energy failure and demyelination induce inappropriate function and distribution of ion channels, which are commonly observed during the course of neurodegeneraion as imbalanced axonal ion homeostasis. After demyelination, Na + channels, voltage-gated Ca 2+ channels, acid-sensing ion channels and transient potential receptors are dispersed diffusely along the bare axolemma after demyelination, eventually leading to axonal Ca 2+ overload. [23] [24] [25] In contrast, modification of the dysregulated distribution of ion channels might prevent neurodegeneration and therefore provide a novel neuroprotective intervention for MS therapies. 26 
Immune-mediated neuronal damage associated with neurodegeneration
The fact that global inflammatory responses in the CNS of SP-MS patients are much less apparent compared with acute disease makes us underscore the significance of underlying smoldering inflammation for the development and progression of SP-MS. Although sustained low-grade inflammation is attributed to intermittent stimulation of innate immunity, including activation of microglia and dendritic cells in the CNS, the precise mechanism of this activation remains elusive. 27, 28 SP-MS by definition is a progressive form of disease preceded by repetition of relapse/remission with massive inflammation through activation of acquired immunity. Although numbers of infiltrated immune cells at the progressive stage of MS are relatively low, it does not necessarily exclude the possibility that those immune cells are involved in the pathogenesis of SP-MS. Actually, siponimod (BAF312), a novel selective sphingosine-1-phosphate receptor modulator, has been shown to delay disability progression in patients with SP-MS in a recent clinical trial, 29 and ocrelizumab, a humanized anti-CD20 monoclonal antibody, was shown to reach the primary disability end-point in PP-MS patients, 30 suggesting the possible involvement of immune components, such as T cells and B cells, in the pathogenesis of inflammatory CNS diseases with neurodegenerative symptoms. There is a great deal of evidence that implies the involvement of immune components, as discussed below.
CNS T cells
The degree of inflammation observed in RR-MS is gradually less apparent in SP-MS in parallel with increased age and disease duration. Peripheral immune activation targeting the CNS causes MS pathology during the early phases of RR-MS. In contrast, inflammatory immune responses in SP-MS are more compartmentalized within CNS due to the recovery of the damaged BBB. Therefore, it is difficult to monitor ongoing immune responses within the CNS in SP-MS. In addition, a potential association between Epstein-Barr virus infection and the development of MS is well described. Epstein-Barr virus antigens derived from lytic cycle proteins trigger activation of CD8+ T cells, which induce accumulation of CD8+ T cells into cortical CNS lesions with MS. 31 In vitro analysis showed that CD8+ T cells kill neurons through the Fas/FasL-dependent pathway in a major histocompatibility complex class I-restricted manner. 32, 33 Furthermore, cytotoxic T cells release pro-inflammatory cytokines, such as IFN-c, tumor necrosis factor (TNF)-a and cytolytic molecules (granzyme, perforin and granulysin). 34, 35 IFN-c induces glutamate neurotoxicity through the IFN-c/alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) GluR1 receptor complex. 36 TNF-a enhances neuronal cell death through TNF receptor p55, and the combination of granzyme and perforin harms neurons. 37 Although cytotoxic T cells might be involved in the pathogenesis of SP-MS, the underlying mode of action of how they damage neurons in MS is still controversial. Pathogenic involvement of CD4+ T cells in SP-MS is much less clear, but the above-mentioned microglial activation might actively present antigens and stimulate CD4+ T cells infiltrated into the CNS. 16 In a number of in vitro studies, TNF-related apoptosis-inducing ligand secreted by CD4+ and CD8+ cells induces apoptosis of neurons. [38] [39] [40] Perforin and granzyme A/B secreted by CD8+ (and to a lower degree by CD4+ cells) might induce antigen-dependent neuronal apoptosis. 35 Fas induces apoptosis of neurons after binding to Fas ligand expressed on CD8+ T cells. 32 In addition T cell-derived inflammatory cytokines sensitize glutamate receptors and increase glutamate excitotoxicity. Namely, TNF-a augments AMPA-induced toxicity in Purkinje neurons by increasing intracellular calcium flux, 41 and IFN-c modulates AMPA receptor clustering and synaptic activity in hippocampal cell culture. 42 Furthermore, IL-17 promotes N-methyl-D-aspartate NR1 phosphorylation and induces thermal hyperalgesia. 43 Recently, we have identified another subset of CD4+ T cells constitutively expressing eomesodermin (Eomes) that exert unexpected neurotoxic property and might be relevant to the pathogenesis of SP-MS as described below. 10 
CNS B cells
The function of B cells potentially relevant to pathogenesis of SP-MS is the active production of diseasepromoting antibodies, secretion of pro-inflammatory cytokines that might modify function of other immune cells and antigen presentation through cognate interaction with corresponding T cells. Abnormal B-cell responses for cytokine production are suggested to trigger T-cell-mediated disease progression in MS. 44 Interestingly, comparative analysis of the B-cell repertoire derived from the brain tissue of progressive MS patients showed that the majority of B-cell clones use the immunoglobulin G isotype, and show a shared repertoire distribution between meningeal follicles and parenchymal infiltrates. 45 Another report showed that infiltration of plasma cells into the CNS is more frequent in SP-MS than RR-MS. 46 Ectopic formation of FLS and concealed immune responses behind the BBB Ectopic formation of FLS have been found in 40-70% of SP-MS patients, especially in the subarachnoid space of the leptomeninges, close to inflamed bold vessels, but not in PP-MS patients by post-mortem brain dissection. [47] [48] [49] [50] Developmental stages of FLS are diverse, from newly-formed and immature cellular aggregates, to highly-organized cellular mass resembling tertiary lymphoid structures. FLS is composed of a variety of immune cells, including T lymphocytes, B lymphocytes and plasma cells with co-existing follicular dendritic cells. Follicular dendritic cells secrete CXCL13, and induce recruitment and maturation of B cells. 51 Therefore, activation of acquired immunity in this special compartment could contribute to cortical pathology in SP-MS. 52, 53 This is of particular relevance to the progressive form of MS where the integrity of BBB is recovered, making CNS an isolated compartment independent of peripheral immunological properties. Interestingly, cortical demyelination, neurodegeneration and brain atrophy show a positive correlation with diffuse inflammatory infiltrates of immune cells and formation of FLS in the leptomeninges, suggesting that immune activation in the CNS contributes to cortical pathology in progressive MS. 47, 52, 53 Of note, a clear gradient neuronal loss is observed in grey matter lesions and normal-appearing grey matter in the motor cortex of follicle-positive SP-MS cases. This is greater in superficial cortical layers nearer the pial surface than in inner cortical layers accompanied by glia limitans damage with astrocyte loss. Interestingly, the density of activated microglia shows an opposite gradient with numbers of neurons in both grey matter lesions and normal-appearing white matter only in follicle-positive SP-MS cases. These data imply that cytotoxic factors diffusing from the meningeal compartment might play an essential role in the development of subpial cortical lesions and the consequent increase in clinical disability. 53 Nevertheless, some follow-up studies have not successfully observed substantial perivascular infiltration in intracortical lesions in post-mortem brains from patients with longstanding progressive MS. Considering that development of SP-MS is preceded by a number of relapses and remissions concomitant with inflammatory immune responses during the course of RR-MS, these data could suggest that formation of FLS requires repeated inflammatory responses in the CNS and might be primarily formed during the relapsing-remitting phase of the disease. In other words, formation of FLS might be unstable, relatively short-lived and intermittently structured after the development of active white matter lesions (Amit Bar-Or, Special symposium at the Japanese Society of Neuroimmunoly meeting 2017).
Recent progress in clinical trials of ocrelizumab for PP-MS 29 and siponimod (BA312) for SP-MS 
Aging
It is quite important to point out that above-mentioned chronic low-grade immune activation is one of the typical features of aging (inflamm-aging) and of chronic viral infection, such as cytomegalovirus, human immunodeficiency virus 1, human hepatitis virus B and so on. [54] [55] [56] [57] Interestingly, repeated exposure to ordinary protein antigens induces so-called immunosenescence, which is a shared immunological status in patients with chronic inflammatory diseases, such as MS. For example, expansion of CD4+ CD28neg effector memory T cells is commonly observed with aging, as well as in some autoimmune disease patients including MS. 56, [58] [59] [60] Typical features of CD4+ CD28neg T cells include resistance to apoptosis and refractory to regulatory T-cell-mediated suppression. 55, 58, 61 In addition, these CD4+ CD28neg T cells usually express higher levels of adhesion molecules and acquire cytolytic properties. 60, 61 CX3CR1, fractalkine receptor, is exclusively expressed in CD4+ CD28neg T cells, and drives their recruitment into the CNS of MS patients. 62 Aging also affects the phenotype of conventional T-cell subsets. For instance, accumulation of functionally impaired Th17 cells and regulatory T cells is apparent, and CD8+ T cells acquire increased cytotoxic property upon aging. Furthermore, the diversity of the B-cell repertoire decreases and, conversely, cross-reactivity to self-antigens increases. 63 Infiltration of plasma cell into the CNS is more frequent in SP-MS than RR-MS, possibly due to the dominant expansion of the plasma cells associated with aging. 46 Taken together, senescent immune cells with senescent properties might not be as functional as normal immune cells with adolescent properties, and the previously unappreciated influence of aging on immune cell functions and their responses to disease-modifying therapy must be reconsidered in the future in order to unveil the enigmatic pathogenesis of autoimmune diseases with chronic low-grade immune activation, such as SP-MS Novel mechanism and biomarker of chronic progressive multiple sclerosis Acute experimental autoimmune encephalomyelitis and RR-MS are controlled by NR4A2-dependent Th cells Animal models for human diseases, such as MS, provide a great opportunity to gain clear-cut insights into the underlying pathogenic mechanisms of the disease. The most well-accepted animal model for MS is experimental autoimmune encephalomyelitis (EAE), where mice are immunized with myelin peptides derived from myelin oligodendrocyte glycoprotein, proteolipid protein and so on emulsified in complete Freund's adjuvant to induce differentiation of autoreactive effector T cells. 64, 65 Once these encephalitogenic T cells infiltrate into the CNS, they secrete inflammatory cytokines, including IL-17 and IFN-c, and recruit other inflammatory immune cells to promote damage to myelin and induce ascending paralysis, a typical sign of EAE.
Previously, we identified NR4A2 as one of the orphan nuclear receptors that is selectively upregulated in CD4+ T cells derived from RR-MS patients. 66, 67 Interestingly, upregulation of NR4A2 is reproducible in CD4+ T cells infiltrating the CNS and in peripheral blood of mice with EAE. 66, 68 Further analysis showed that NR4A2 plays a critical role in the expression of genes associated with the development of Th17 cells, such as IL-17, IL-23 receptor and IL-21, by Th cells without affecting their expression of RORct. 68 In addition, systemic treatment with NR4A2-specific siRNA reduced IL-17 production by effector Th cells and protected mice from EAE signs.
Conditional knockout (cKO) of NR4A2 gene mice (NR4A2cKO mice) develop significantly ameliorated disease together with reduced accumulation of Th17 cells in the CNS, suggesting the crucial role of NR4A2 on the development of EAE. 10 Unexpectedly, NR4A2cKO mice developed late EAE-like signs, suggesting that clinical stages of myelin oligodendrocyte glycoprotein (35-55)-induced EAE in C57BL/6 mice can be separated into two phases: an NR4A2-dependent early/acute phase and an NR4A2-independent late/chronic phase (Fig. 1) .
Late EAE and SP-MS are controlled by Eomesexpressing novel Th cells
Passive transfer of Eomes+ Th cells isolated from mice with late/chronic EAE induced unexpected rapid worsening of EAE after transfer into NR4A2cKO mice before the onset of late/chronic EAE, suggesting the existence of a pathogenic component within Th cells obtained from mice with late/chronic EAE. In the late/chronic phase of EAE, CNS-infiltrating Th cells showed higher expression of the Eomes gene, which is a transcription factor associated with cytotoxic T cells and natural killer cells. 10 Although Eomes expression by Th cells in the context of autoimmune inflammation has not been previously described, accumulation of Eomes+ Th cells in the CNS was persistent and stable over 15 weeks after induction of EAE. Systemic administration of Eomes-specific siRNA or NR4A2/Eomes double conditional KO mice abolished the clinical signs of late/chronic EAE. Therefore, the development of late/chronic EAE was promoted by pathogenic Eomes+ Th cells infiltrating the CNS.
The frequency of Eomes+ Th cells in peripheral blood mononuclear cells of either healthy controls or patients with RR-MS is 2-12% within total CD4+ T cells, which was consistent with a recent report. 69 In contrast, the proportion of Eomes+ Th cells was significantly increased in patients with SP-MS, showing the striking resemblance with late/chronic EAE. Importantly, accumulation of Eomes+ Th cells was not correlated with patients' background, such as age, sex, treatment or current status of disability, in individual patients. Proportions of Eomes+ Th cells were further enriched in the cerebrospinal fluid from patients with SP-MS, indicating their propensity for moving to the site of autoimmune inflammation. Therefore, Eomes+ Th cells might also play a key pathogenic role in SP-MS.
Mouse and human Eomes+ Th cells from SP-MS patients have been shown to express cytotoxic markers granzyme B and show mobilization of CD107a, also known as lysosomal-associated membrane protein 1 upon stimulation, sharing the phenotype with conventional cytotoxic T cells. Furthermore, as shown in a recent report, a perforin-independent mechanism of cytotoxicity seems to be involved in neuronal cell death. 70 Accordingly, administration of granzyme B-specific siRNA or specific inhibitors for protease-activated receptor-1 significantly inhibited the development of late-chronic EAE, implying that the perforin-independent mechanism of neuronal death can be mediated by granzyme B/protease-1-activated receptor interactions ignited by infiltrating Eomes+ Th cells. These data raise the possibility that granzyme B-releasing Eomes+ Th cells might help to solve the cellular and molecular mechanisms of neurodegeneration associated with pathogenesis of SP-MS (Fig. 2 ).
Conclusion and future perspectives
A long history of MS study with numerous publications certifies the usefulness of EAE for investigating the pathogenic mechanism of MS. [5] [6] [7] However, it is surprising that myelin oligodendrocyte glycoprotein peptide induced monophasic signs of EAE in C57BL/6 mice, the most commonly used model of EAE is composed of at least two independent pathomechanisms. As aforementioned, early EAE is NR4A2-dependent, Th17 cell-mediated acute disease, resembling the pathogenesis of RR-MS. Intriguingly, in the absence of NR4A2 in Th cells, mice develop another form of late disease that is Eomes-dependent, which shows significant overlap in the pathogenesis of chronic CNS inflammation associated with persistent and progressive neurological dysfunctions typically observed in SP-MS. 10 As summarized in the [73] [74] [75] Therefore, the developmental processes of Eomes+ Th cells in the CNS under chronic inflammation will provide other therapeutic means for preventing transition of the disease from RR-MS to SP-MS (Fig. 3) . patients. Recently, we investigated an intrinsic involvement of major histocompatibility complex class II-positive antigen-presenting cells for the development of Eomes+ Th cells in inflamed CNS and showed that prolactin ectopically produced by CNS-infiltrating antigen-presenting cells plays a critical role for induction of Eomes expression in Th cells. Therefore, prevention of Eomes+ Th cell generation could be considered for preventing transition of the disease from RR-MS to SP-MS. Classification criteria for progressive MS were recently revised, and divided into four categories with two-dimensional parameters of active inflammation and clinical disease progression. 8 Although active inflammation reflects the presence of clinical relapses or magnetic resonance imaging-based symptoms, imaging techniques are not necessarily sensitive enough to detect smoldering CNS inflammation in SP-MS patients, and Expanded Disability Status Scale score is not incisive enough to estimate the degree of ongoing disease progression. Therefore, identifying and determining novel biomarkers that reflect ongoing disease progression in MS is a pressing issue. It is hoped that the frequency of Eomes+ Th cells and the related parameters could provide a novel measure effective for the diagnosis of progressive MS.
Currently, further investigation is underway to fully understanding the pathogenic mechanisms of SP-MS. The author believes that Eomes+ Th cells and their neighboring cellular component accumulated in the CNS would be a great candidate for the development of novel therapeutic interventions for SP-MS.
